Moderna cancer vaccine succeeds in Phase 3, AI powers personalized mRNA treatment
HealthcareAIGuy · x · 2026-08-20
Moderna and Merck's individualized mRNA cancer treatment has met its primary endpoints in a Phase 3 trial.
Core Workflow:
- Sequence the patient's tumor.
- Use AI to identify mutations most likely to trigger an immune response.
- Manufacture a personalized mRNA treatment encoding up to 34 neoantigens.
Clinical Data:
- The prior Phase 2 melanoma trial showed a 49% lower risk of recurrence or death and a 59% lower risk of distant metastasis or death.
- The current Phase 3 trial involving 1,137 patients confirmed these results.
More from Research
- Dev critiques compiling fast programs into slow neural nets: fun, but not useful — ctjlewis · 2026-10-16
- New paper uses revealed-preference methods to unpack why AI agents cooperate — brwilder · 2026-10-16
- Logit lens on a Beat Saber finetune reveals it reuses language grammar circuits — ctjlewis · 2026-10-16
- 128×128 record stands: how intermediate-work experiments foreshadowed reasoning models — ctjlewis · 2026-10-16
- TeamFusion: preference-based AI proxies debate to preserve minority views in team decisions — burkov · 2026-10-16
- MIT's C-GMT gives humanoid robots whole-body compliance without sacrificing motion tracking — MIT_CSAIL · 2026-10-16